Promacta
Active Ingredient(s): EltrombopagFDA Approved: * November 20, 2008
Pharm Company: * GLAXOSMITHKLINE
Category: Blood Clotting (Hemostasis)
Eltrombopag, sold under the brand name Promacta among others, is a medication used to treat thrombocytopenia (abnormally low platelet counts) and severe aplastic anemia. Promacta (eltrombopag) is known as Revolade® outside the U.S. and is marketed worldwide by Novartis.[5] It is a thrombopoietin receptor agonist.[3] Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals and is transferred to Nova... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.1 Discussion
Dosage List
Promacta 25 mg Oral Tablet, Film Coated
NDC: 0078-0685
Labeler:
Novartis Pharmaceuticals Corporation
Promacta 50 mg Oral Tablet, Film Coated
NDC: 0078-0686
Labeler:
Novartis Pharmaceuticals Corporation
Promacta 12.5 mg Oral Tablet, Film Coated
NDC: 0078-0684
Labeler:
Novartis Pharmaceuticals Corporation
Promacta 75 mg Oral Tablet, Film Coated
NDC: 0078-0687
Labeler:
Novartis Pharmaceuticals Corporation